Key result
Ridogrel, a thromboxane receptor antagonist and synthase inhibitor, demonstrated safety and efficacy in post-myocardial infarction patients and reduced blood pressure in animal models.
Ridogrel is a dual-acting antiplatelet agent with potential antihypertensive properties that may offer theoretical advantages over aspirin.
Should not yet change post-MI therapy; hypothesis-generating for dual-action agents and warrants RCTs.
Ridogrel is a member of the class of drugs known as thromboxane receptor antagonists/thromboxane synthase inhibitors or TRASIs. In vitro and in vivo studies have confirmed it selectively reduces thromboxane A2 (TXA2) synthesis in platelets and elsewhere, while leaving the synthesis of other eicosanoids unchanged or even increased. Theoretically, it should produce a greater overall antithrombotic effect than aspirin. Some animal and human studies support this concept. A large phase III study confirmed the safety and efficacy of ridogrel in patients following myocardial infarction. It may also be useful in other clinical situations. In spontaneously hypertensive‐stroke prone rats, ridogrel reduces blood pressure, but increases plasma renin activity. The antihypertensive effect is potentiated by losartan. an angiotensin‐type I receptor antagonist. Ridogrel may also have efficacy in pregnancy induced hypertension, inflammatory bowel disease, and asthma.
No takes yet. Share an insight, caveat, or question.
Wilson et al. (2000) conducted a review in myocardial infarction. Ridogrel was evaluated. Ridogrel, a thromboxane receptor antagonist and synthase inhibitor, demonstrated safety and efficacy in post-myocardial infarction patients and reduced blood pressure in animal models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: